Pathophysiology and Clinical Implications of Dysautonomia

General Mechanisms

• Dysautonomia arises from dysfunction of the autonomic nervous system at peripheral nerves, autonomic ganglia, spinal cord, or brain levels, producing cardiovascular, respiratory, gastrointestinal, urinary, reproductive, ocular, and sudomotor abnormalities. 1

Orthostatic Hypotension (Autonomic Failure)

• Baroreceptor afferents from the carotid sinus and aortic arch convey pressure information to the vasomotor center in the medulla, and impairment of this pathway underlies orthostatic hypotension. 2
• The efferent autonomic outflow controls heart rate and peripheral vascular tone; inadequate increase in vascular tone is the pivotal defect in orthostatic hypotension. 3
• Degeneration of central autonomic nuclei and/or peripheral autonomic denervation produces orthostatic hypotension and syncope. 2
• In primary or secondary autonomic failure, sympathetic fibers cannot raise total peripheral vascular resistance when upright, leading to venous pooling below the diaphragm and reduced venous return. 4

Postural Tachycardia Syndrome (POTS) Phenotypes

• Hypovolemic POTS – characterized by reduced circulating blood volume. 1
• Neuropathic POTS – associated with patchy peripheral autonomic denervation or peripheral neuropathy. 5
• Primary Hyperadrenergic POTS – marked by an excessive hyperadrenergic state. 5
• Approximately 40 % of individuals with POTS report a preceding upper‑respiratory or gastrointestinal viral infection, suggesting an immune trigger. 6

Association with Connective‑Tissue Disorders (hEDS)

• A mechanistic link exists among hypermobile Ehlers‑Danlos syndrome (hEDS), POTS, and mast‑cell activation syndrome, implicating connective‑tissue abnormalities. 7
• Skin biopsies in hEDS reveal abnormal collagen‑fibril architecture that disrupts fibroblast adhesion and cytoskeletal responses. 7
• hEDS tissue exhibits reduced mechanical stiffness compared with control subjects, potentially facilitating vascular laxity. 7
• Early or excessive mast‑cell degranulation in hEDS produces multisystem symptoms affecting skin, gastrointestinal, respiratory, and cardiovascular systems. 7

Diabetic Cardiovascular Autonomic Neuropathy (CAN)

• Progressive autonomic dysfunction in diabetes correlates with glycemic control, disease duration, age, and microvascular complications. 8
• Sympathetic fiber impairment in CAN limits appropriate vasoconstriction, contributing to orthostatic intolerance. 8
• Altered baroreflex sensitivity and an imbalance of sympathetic‑vagal tone are characteristic of diabetic CAN. 8

Clinical Manifestations of Dysautonomia

• Cardiovascular – resting tachycardia, exercise intolerance, orthostatic hypotension, and QT‑interval prolongation. 9
• Peripheral Vascular – increased peripheral blood flow, heightened arteriovenous shunting, and loss of protective cutaneous vasomotor reflexes. 8
• Gastrointestinal – nausea, abdominal pain, vomiting, diarrhea, abdominal distension, and severe constipation due to visceral hypersensitivity or dysmotility. 6
• Neuro‑cognitive & Autonomic – cognitive impairment, bladder dysfunction, orthostatic dizziness, fatigue, blurred vision, and generalized weakness. 10

Diagnostic Recommendations

• Objective testing (e.g., tilt‑table testing, heart‑rate variability, baroreflex assessment) is required to confirm autonomic dysfunction; reliance on subjective symptom reports alone is insufficient. 9

Infection‑Triggered Dysautonomia

• Viral infections, including SARS‑CoV‑2, can precipitate dysautonomia through autoimmune mechanisms; up to two‑thirds of individuals with prolonged COVID‑19 meet criteria for autonomic dysfunction. 6

Management of Persistent POTS When Conservative Therapy Fails

Excluding Secondary Causes

• Persistent orthostatic tachycardia that does not improve with adequate conservative therapy is most often due to an unrecognized secondary cause or comorbidity that requires specific treatment rather than primary POTS pathophysiology alone. 11
• Prolonged bed‑rest or severe deconditioning can mimic POTS hemodynamics, but standard POTS therapies are ineffective until the underlying deconditioning is reversed. 11
• Severe hypovolemia caused by inadequate fluid intake, diuretic use, or gastrointestinal losses (e.g., chronic vomiting, gastroparesis, diarrhea) prevents volume‑expanding treatments from working. 12
• Medications that provoke tachycardia (e.g., stimulants, norepinephrine‑reuptake inhibitors, decongestants) must be identified and discontinued before POTS‑specific therapy is pursued. 11

Diagnostic Clarifications

• Asymptomatic orthostatic tachycardia detected by wearable heart‑rate monitors does not meet criteria for a POTS diagnosis or warrant treatment; such patients generally require reassurance only. 11

Pharmacologic Considerations

• Fludrocortisone should be avoided in patients with migraine because it may exacerbate headache frequency. 12
• Pyridostigmine frequently causes diarrhea and bladder irritation, making it poorly tolerated in individuals with frequent bowel movements or bladder dysfunction. 12
• Fatigue induced by beta‑blockers can undermine adherence to exercise programs, creating a cycle in which medication side‑effects prevent the most effective therapy from being implemented. 12
• All current pharmacologic recommendations are derived from small acute trials or retrospective series; no long‑term randomized controlled trials exist, so therapy must be empiric and closely monitored. Evidence level: low. 12

Supportive Therapies and Exercise Adherence

• Beta‑blocker‑related fatigue (see above) may necessitate dose adjustment or alternative agents to enable patients to complete the recommended semi‑recumbent exercise regimen (minimum 4 sessions/week, ≥30 min each). 12

Safety of Intravenous Volume Expansion

• Routine chronic intravenous saline infusion is contraindicated because of infection and thrombosis risks; it should be reserved only for exceptional cases with severe gastrointestinal dysfunction that limits oral fluid intake. Evidence level: low. 12

Lack of Established Association Between POTS and Ankylosing Spondylitis

Guideline Statements

• The 2015 American College of Rheumatology/Spondylitis Association of America guideline for ankylosing spondylitis does not mention autonomic dysfunction or postural orthostatic tachycardia syndrome as an associated condition, indicating no recognized link between the two diseases. 13

Symptom Overlap Between the Conditions

• Both ankylosing spondylitis and POTS commonly affect young adults and can present with fatigue, exercise intolerance, and reduced quality of life, which may create diagnostic confusion. 13

Cardiovascular Manifestations in Ankylosing Spondylitis

• Patients with ankylosing spondylitis may develop cardiovascular complications such as conduction abnormalities and aortitis; these are structural in nature rather than autonomic dysregulation. 13

Diagnostic Approach When Orthostatic Symptoms Co‑exist

• Objective orthostatic vital‑sign testing (5 min supine followed by standing measurements at 1, 3, 5, and 10 minutes) should be performed to determine whether POTS diagnostic criteria are met. 13
• POTS is defined by a sustained heart‑rate increase of ≥30 bpm (≥40 bpm in adolescents) upon standing, a standing heart rate ≥90 bpm, and a temporal correlation between symptoms and documented tachycardia. 13

Medication Considerations

• Non‑steroidal anti‑inflammatory drugs, the primary pharmacologic therapy for ankylosing spondylitis, are not typically associated with orthostatic tachycardia; however, other medications should be reviewed and excluded as potential causes of tachycardia. 13

Role of Deconditioning

• Severe deconditioning secondary to poorly controlled ankylosing spondylitis can produce orthostatic intolerance that often improves with better disease control and targeted physical‑therapy interventions. 13

Independent Management Recommendations

• Ankylosing spondylitis and POTS should be managed separately according to their respective evidence‑based treatment algorithms, as outlined in the relevant specialty guidelines. 13